GH Research says H1 loss widens as R&D spending rises on GH001 clinical, technical development workPUBT·Aug 6 at 06:26 AMGHRS-1.10%
GH Research publishes corporate presentation on ultra-rapid, durable remission data for TRD treatment GH001PUBT·Aug 6 at 06:19 AMGHRS-1.10%
Macro Crosscurrents Shape Divergent Paths for 10 Off-the-Radar EquitiesGlobal Report·Aug 4 at 04:17 AMGHRS-1.10%BEP-4.56%
Is GH Research (GHRS) Fully Valued Following Its Share Price Surge?Simplywall·Aug 1 at 02:22 PMGHRS-1.10%
Global capital pivots to idiosyncratic U.S. assets as macro headwinds intensifyGlobal Report·Jul 24 at 04:13 AMNPT+1.59%NG-3.61%
Q1 2026 Overhauls: Strategic Pivots Across Retail, Energy, and Niche TechGlobal Report·Jul 22 at 04:18 AMSIGA+1.54%ADUR-2.24%
Capital in the Crevices: What the Market's Long Tail Tells Us About 2026Global Report·Jul 19 at 04:13 AMENVX-13.91%DLB-0.29%
Tech and Biotech Sectors See Specialized Consolidation Amid 2026 Regulatory MilestonesGlobal Report·Jul 18 at 04:12 AMUCAR+12.27%BETA+3.98%
Why Is GH Research Stock Trading Higher on Thursday?benzinga_article·Jul 16 at 11:36 AMGHRS-1.10%ATAI+0.62%
Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions | LLY Stock NewsStockTitan·Jul 15 at 09:45 PMLLY+3.10%ATAI+0.62%
